Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

PEAK PlasmaBlade™ 4.0 Versus Traditional Electrosurgery in Mastectomy (PRECISE)

This study has been terminated.
(Termination due to acquisition of PEAK Surgical by Medtronic)
Information provided by (Responsible Party):
Medtronic Surgical Technologies Identifier:
First received: July 21, 2009
Last updated: January 3, 2013
Last verified: January 2013

July 21, 2009
January 3, 2013
June 2009
December 2011   (final data collection date for primary outcome measure)
  • Total Serous Drainage (mL) From Time of Drain Placement to Removal. [ Time Frame: 0 to 10 days postoperatively ] [ Designated as safety issue: No ]
  • Area of Skin Necrosis Measured With a Standard Ruler [ Time Frame: 1 and 6 weeks postoperative ] [ Designated as safety issue: No ]
Total serous drainage (mL) from time of drain placement to removal. [ Time Frame: First 10 Post-operative days ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00943605 on Archive Site
Pain Score by Visual Analog Scale, Narcotic Consumption, Operative Time, Time to Surgical Drain Removal [ Time Frame: 0 to 10 days postoperatively ] [ Designated as safety issue: No ]
Pain score by visual analog scale and narcotic consumption. [ Time Frame: First 10 Post-operative days ] [ Designated as safety issue: No ]
Not Provided
Not Provided
PEAK PlasmaBlade™ 4.0 Versus Traditional Electrosurgery in Mastectomy
A Prospective, Randomized, Controlled Superiority Study to Evaluate Use of the PEAK PlasmaBlade™ 4.0 in Mastectomy

The objective of this clinical study is to evaluate the incidence of partial skin necrosis following modified-radical mastectomy with or without same-day (two-stage) reconstruction with the PEAK PlasmaBlade 4.0; to monitor and record operative performance, post-operative pain, drain output, and skin scarring following surgery; and to compare these endpoints to the current standard of care (SOC).

Mastectomy is a surgical procedure performed to remove breast tissue that contains cancer, or has a high probability of containing cancer. During the procedure, a scalpel is used for the skin incision and a traditional electrosurgical device is used to cut away the breast tissue from the chest and control bleeding. Once the breast tissue is removed the remaining skin edges are brought together with sutures.

Following mastectomy, the most common complication is persistent serous wound drainage and seroma, a collection of fluid in the closed surgical space. To help prevent this complication a tissue drain is used to remove serous fluid from the surgical space via bulb suction. The rate of serous fluid collection is used to determine the time the drain remains in place. Although suction drains help reduce seroma formation, prolonged use may delay healing, cause injury, and increase the risk of infection and patient discomfort.

The PEAK PlasmaBlade™ uses pulsed radiofrequency (RF) energy to enable precision cutting and coagulating at the point of application, without the thermal damage to surrounding tissues that is normally seen with traditional electrosurgery. The PlasmaBlade has received FDA clearance for use in plastic, general, and ENT surgery, and has demonstrated significantly reduced serous drainage in tissue reduction surgeries, like mastectomy.

This multi-site study was granted IRB approval and conducted between June 2009 and January 2011. Potential subjects were screened against the inclusion and exclusion criteria of the study protocol and were then required to provide informed consent prior to enrollment. Following enrollment, subjects were prospectively randomized to the SOC or PlasmaBlade (PB or PEAK) study groups and scheduled for mastectomy with or without same day reconstruction.

Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
  • Device: Scalpel and Traditional Electrosurgery
    The PEAK PlasmaBlade will be used for the entirety of the breast reduction, including the skin incision.
  • Device: PEAK PlasmaBlade
    The entirety of the mastectomy will be performed with the PEAK PlasmaBlade, including the skin incision.
  • Active Comparator: Standard of Care
    Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
    Intervention: Device: Scalpel and Traditional Electrosurgery
  • Experimental: PEAK PlasmaBlade
    The entirety of the mastectomy will be performed with the PEAK PlasmaBlade, including the skin incision.
    Intervention: Device: PEAK PlasmaBlade
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
March 2012
December 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Age between 20 and 70 years old
  2. Physically healthy, stable weight
  3. Requiring single or bilateral simple mastectomy, with or without sentinel lymph node biopsy
  4. Subject must understand the nature of the procedure and provide written informed consent prior to the procedure
  5. Subject must be willing and able to comply with all follow-up evaluations

Exclusion Criteria:

  1. Age younger than 20 or greater than 70 years old
  2. Anticoagulation therapy which cannot be discontinued
  3. Prior external beam or implanted radiotherapy
  4. Tobacco use (any kind)
  5. Infection (local or systemic)
  6. Cognitive impairment or mental illness
  7. Severe cardiopulmonary deficiencies
  8. Known coagulopathy
  9. Immunocompromised
  10. Kidney disease (any type)
  11. Desiring or requiring same-day breast reconstruction
  12. Prior breast reduction or augmentation surgery
  13. Unable to follow instructions or complete follow-up
  14. Currently taking any medication known to affect healing
  15. Subjects who are status-post gastric banding or gastric bypass
  16. Currently enrolled in another investigational device or drug trial
  17. Time from most recent neoadjuvant therapy less than 4 weeks
20 Years to 70 Years
Contact information is only displayed when the study is recruiting subjects
United States
PEAK VP-00074
Medtronic Surgical Technologies
Medtronic Surgical Technologies
Not Provided
Principal Investigator: Teresa Ponn, MD Elliot Breast Health Center
Principal Investigator: Edward Dalton, MD Elliot Breast Health Center
Principal Investigator: Richard Fine, MD Advanced Breast Care
Principal Investigator: Peter Naruns, MD Midpeninsula Surgical Associates
Principal Investigator: Saul Eisenstat, MD Midpeninsula Surgical Associates
Principal Investigator: Michael Schultz, MD St. Joseph Medical Center
Medtronic Surgical Technologies
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP